The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.
Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.
By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.
Head of the Stem Cell R&D Transformational Research Unit (Corporate Vice President), responsible for the entire R&D value chain, from research, manufacturing for clinical de-velopment (CMC), non-clinical, clinical development, regulatory and business develop-ment, project management and operations.
2002-2018: Therapeutic area head for diabetes (type 1 and 2) and stem cells in Global Research at Novo Nordisk. Previous areas of responsibility in global research includes obesity and NASH. Previous positions include.
2001-2002: Executive Chief Scientific Officer Inoxell Inc. Denmark, focusing on finding novel drug tar-gets.
1998-2001: Head of Islet Discovery Research, Novo Nordisk Denmark: Working with type 2 and type 1 diabetes.
1995-1998: Senior scientist/project manager at ZymoGenetics inc. Seattle USA: Work-ing on type 1 diabetes intervention/prevention and immunology.
1989-1995: Ph.D student and later Staff scientist Hagedorn Research Institute, Gentofte Denmark: Research focus on islet biology and type 1 diabetes.
From 2010 professor in biomedicine at the medical faculty in Copenhagen University. In 2006 awarded the doctor of medical science (DMSc) degree from the medical faculty Copenhagen University Den-mark. Member of the board of directors of JDRF Denmark (vice-chairman).
Besides numerous presentations at international diabetes conferences, published approx. 60 papers in peered reviewed journals mainly on topics of diabetes prediction, prevention and intervention but also on beta cell biology, physiology and immunology.